The existing vaccines authorized for emergency usage did not register kids nor pregnant ladies in their original medical trials, so data on the safety of these vaccines in these populations is sorely lacking. Generex Biotechnology Corporations majority owned public business NuGenerex Immuno-Oncology, Inc. (” NGIO”) is establishing the Ii-Key-SARS-CoV-2 vaccine with an unique emphasis on the advancement of a safe and effective vaccine for the pediatric population and for pregnant ladies, populations with substantial unmet requirement in the COVID vaccine race. Generex/NGIOs other Ii-Key vaccines AE37 for cancer and Ii-Key-H1 for influenza are based on the Ii-Key platform utilized to develop the Ii-Key-SARS-CoV-2 vaccine. We are happy to announce we have picked the Generex/NuGenerex COVID-19 Vaccine due to the fact that of the high probability of success and most importantly due to the fact that of its tested security record, NGIOs vaccine is based on natural amino acids. NuGenerex Immuno-Oncology, Inc.s (NGIOs) proprietary Ii-Key technology offers a SAFE fast course to human protection from the COVID-19 pandemic, and the long-term security profile of Ii-Key vaccines enables NGIO to quickly establish COVID vaccines for our most valued possessions, our kids and pregnant ladies.”
This material was originally published here.
NEW YORK CITY, April 08, 2021 (GLOBE NEWSWIRE)– Last Chance for Childrens (LCFC) Mission is to assist in saving kidss lives anywhere in the world. Due to the COVID-19 pandemic we are now focusing our efforts to assist remove this infection so we could securely and efficiently vaccinate kids in need.
Why do we need a COVID-19 Vaccine for Children and Pregnant Women?
Kids lives have been entirely interrupted by the coronavirus pandemic. To date, none of the vaccines against COVID-19 are authorized by the FDA for usage in children under 12 years old or pregnant women.
The present vaccines approved for emergency situation usage did not register children nor pregnant ladies in their original clinical trials, so information on the safety of these vaccines in these populations is sorely doing not have. As pregnant women have a 70% increased risk of extreme COVID disease, a safe vaccine is desperately needed. And even though children do not generally get extreme COVID, the lack of a vaccine is keeping kids out of school, restricting social interaction, and possibly leaving lots of kids behind. Plus, if we wish to reach herd resistance needed to eradicate the pandemic, we need to vaccinate kids.
Most of these vaccines are based on gene treatment using RNA and DNA vectors that have unknown concerns on duration of protection and long-term safety. The NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 vaccine is based upon natural amino acids using series that imitate the coronavirus spike and structural proteins, and selectively manage choose immune responses that are targeted specifically versus the SARS-CoV-2 infection without using hereditary product.
Generex Biotechnology Corporations bulk owned public business NuGenerex Immuno-Oncology, Inc. (” NGIO”) is establishing the Ii-Key-SARS-CoV-2 vaccine with an unique emphasis on the advancement of a reliable and safe vaccine for the pediatric population and for pregnant ladies, populations with considerable unmet requirement in the COVID vaccine race. The business has actually completed GMP manufacturing of its Ii-Key-SARS-CoV-2 peptides and strategies to submit its FDA IND to initiate scientific trials as soon as possible. NGIOs objective is to begin the pediatric scientific trials by the Fall of 2021.
A Proven Safe & & Effective Vaccine
Generex/NGIOs other Ii-Key vaccines AE37 for cancer and Ii-Key-H1 for influenza are based on the Ii-Key platform used to develop the Ii-Key-SARS-CoV-2 vaccine. These immunotherapeutic vaccines have been revealed to be safe in scientific trials including hundreds of healthy volunteers and cancer clients.
Anthony S. Crisci, Founder, President, and Chief Executive Officer of Last Chance for Children commented, “After months of research study, education and understanding the unmet need for kids, especially children under 12 and pregnant lady from underserved populations worldwide in medical requirement. We are happy to announce we have actually picked the Generex/NuGenerex COVID-19 Vaccine since of the high possibility of success and most importantly due to the fact that of its proven security record, NGIOs vaccine is based on natural amino acids. NuGenerex Immuno-Oncology, Inc.s (NGIOs) proprietary Ii-Key innovation provides a SAFE rapid course to human defense from the COVID-19 pandemic, and the long-lasting security profile of Ii-Key vaccines enables NGIO to rapidly develop COVID vaccines for our most valued properties, our kids and pregnant ladies.”
The partnership between Generex/NuGenerex and Last Chance for Children allows for pregnant ladies and select children to get NGIOs vaccine at a special 50 percent off expense … if, and as soon as, authorized by the FDA and made readily available to the public.Last Chance for Children is devoted to raising the required funds, in a fully transparent and fully disclosed model, to straight support NGIO in carrying out the clinical trials needed by FDA. The more cash Last Chance for Children raises for the clinical development of a efficient and safe COVID-19 vaccine, the much faster we can reach herd resistance and get back to a sense of normalcy.
Please visit our website https://www.lastchanceforchildren.org and our Go Fund Me page https://charity.gofundme.com/o/en/campaign/covid-19-vaccine-for-children-and-pregnant-women. This contribution is tax deductible and will save our essential possessions, our pregnant mothers and their kids and all kids, while ensuring our elderly are safe around their families and loved ones.
About Last Chance for ChildrenLast Chance for Children (LCFC), founded in March 2011, is a 501( c)( 3) Non-Profit that steps in where the major illness foundations have actually fallen brief in offering direct comfort and support to the Children and Families impacted by harmful diseases … and genuine Hope for a Cure. The major structures are focused more on supplying info or grants for in some cases arcane academic research study while LCFC is actively assessing public and private business committed to bringing a treatment to market. Please visit our website to find out more https://www.lastchanceforchildren.org
About Generex Biotechnology Corp.Generex Biotechnology Corporation (OTCQB: GNBT) is an integrated health care holding business with end-to-end services for client centric care from rapid medical diagnosis through delivery of personalized treatments. Generex is developing a brand-new sort of health care business that extends beyond standard models supplying support to physicians in an MSO network, and continuous relationships with patients to improve the client experience and access to ideal care. Please check out, https://www.generex.com to find out more.
About NuGenerex Immuno-OncologyNuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a scientific phase oncology company developing immunotherapeutic peptide vaccines for cancer and infectious illness based on the CD4 T-Cell activation platform, Ii-Key. The business has likewise turned its Ii-Key technology on transmittable illness, responding to the coronavirus pandemic with a SARS-CoV-2 vaccine advancement program.
Last Chance for Children Contact: Anthony S. Crisci, Esq., CPAPresident and CEOLast Chance for ChildrenTel: 914.417.9706 Email: anthony@lastchanceforchildren.orgFax: 818.301.5165 www.lastchanceforchildren.org.
Generex Contact: Todd FallsTel: 1-800-391-6755 Extension 222 Email: info@nugenerexio.com.
